Fortrea Holdings (NASDAQ:FTRE) has been analyzed by seven analysts over the past three months, revealing a wide range of perspectives from bullish to bearish.
The table below provides a quick overview of their recent ratings, showing the changing sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat bullish | Indifferent | Somewhat bearish | Bearish | |
|---|---|---|---|---|---|
| Total reviews | 2 | 1 | 3 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1 million ago | 1 | 1 | 0 | 0 | 0 |
| 2M ago | 1 | 0 | 2 | 0 | 0 |
| 3M ago | 0 | 0 | 0 | 1 | 0 |
To provide deeper insights, analysts have set 12-month price targets, which indicate an average price target of $17.29, along with a high estimate of $25.00 and a low estimate of $10.00. The current average exceeds the previous average price target of $10.57 and is up 63.58%.
Investigating analyst ratings: A comprehensive study
A clear picture of the perception of Fortrea Holdings among financial experts is painted with an in-depth analysis of recent analyst actions. The overview below provides an overview of the top analysts, their recent evaluations and adjustments to ratings and price targets.
| Analyst | Analyst firm | Action taken | Judgement | Current price target | Prior price target |
|---|---|---|---|---|---|
| Charles Rhee | TD Cowen | Increases | Delay | $15.00 | $7.00 |
| Jail Dra Singh | Truist effects | Increases | Buy | $22.00 | $12.00 |
| Elizabeth Anderson | Evercore ISI Group | Increases | Surpass | $25.00 | $14.00 |
| Ann Hynes | Mizuho | Increases | Neutral | $13.00 | $11.00 |
| Luke Sergott | Barclays | Increases | Equal weight | $15.00 | $10.00 |
| Patrick Donnelly | Citi Group | Increases | Buy | $21.00 | $12.00 |
| Luke Sergott | Barclays | Increases | Underweight | $10.00 | $8.00 |
Key insights:
- Action taken: Analysts adapt their recommendations to changing market conditions and business performance. Whether they ‘maintain’, ‘increase’ or ‘decrease’ their position, it reflects their reaction to recent developments regarding Fortrea Holdings. This information provides a snapshot of how analysts perceive the current state of the company.
- Judgement: Analysts provide comprehensive analysis and provide qualitative ratings ranging from ‘Outperform’ to ‘Underperform’. These ratings reflect expectations for Fortrea Holdings’ relative performance compared to the broader market.
- Price targets: Analysts understand forecasts and provide estimates for the future value of Fortrea Holdings. Examining current and past objectives provides insight into changing analyst expectations.
Considering these analyst ratings in combination with other financial indicators can provide a comprehensive insight into Fortrea Holdings’ market position. Stay informed and make informed decisions with our rating table.
Stay up to date with Fortrea Holdings analyst ratings.
If you’re interested in following the news and performance of small cap stocks, you can start here.
About Fortrea Holdings
Fortrea is a global late-stage contract research organization providing comprehensive Phase 1 through Phase 4 clinical trial management, clinical pharmacology and patient access solutions. The company partners with emerging and large biopharmaceutical, medical device and diagnostic companies to conduct their clinical trials as a functional service provider and full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired through its 2015 purchase of Covance for $6.1 billion. Fortrea has 19,000 employees spread across 90 countries.
The economic impact of Fortrea Holdings: an analysis
Market Capitalization Analysis: The company’s market capitalization is below the industry average, which suggests that the company is relatively smaller than peers. This could be due to several factors, including perceived growth potential or operational scale.
Sales growth: Over the 3M period, Fortrea Holdings showed positive performance, with revenue growth of 3.91% as of September 30, 2025. This reflects a substantial increase in the company’s revenue results. Compared to others in the healthcare industry, the company faces challenges and is achieving a growth rate that is lower than the average of its peers.
Net margin: Fortrea Holdings’ net margin exceeds industry standards, underscoring the company’s exceptional financial performance. With an impressive -2.27% net margin, the company manages costs effectively and achieves strong profitability.
Return on Equity (ROE): Fortrea Holdings’ ROE is below the industry average, highlighting challenges in using equity capital efficiently. With an ROE of -2.72%, the company may encounter hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Fortrea Holdings’ ROA is below the industry average, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.57%, the company may encounter obstacles in achieving optimal financial returns.
Debt management: With a high debt/equity ratio of 2.04Fortrea Holdings faces challenges in effectively managing its debt levels, indicating potential financial pressure.
Understanding the relevance of analyst ratings
Analysts are specialists within banking and financial systems who typically report for specific stocks or within defined sectors. These people examine companies’ financial statements, participate in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts rate each stock once a quarter.
Some analysts publish their forecasts for metrics such as growth estimates, earnings, and revenue to provide additional guidance to their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are human too and only offer their opinions to investors.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
#Numbers #Analysts #Discuss #Fortrea #Holdings #Stock #Fortrea #Holdings #NASDAQFTRE